PDL-1 expression has already shown us favorable prognosis in treatment of many solid cancers. As per latest advancements, PDL-1 amplification, although rare in solid tumors, has shown response to PD-1/PDL-1 blockade with median progression-free survival of 15.2 months. (Read more)
At a biomarker level, women carrying BRCA2 mutations can now choose between bilateral risk-reducing mastectomy and surveillance as neither directly impact or have proven to improve survival rates for breast cancer. To the contrary, for BRCA1 mutation carriers, bilateral risk-reducing mastectomy not only drastically reduces the risk of developing breast cancer but, as a consequence, also improves breast cancer–specific survival when compared to surveillance. (Read more)
For yet another solid cancer i.e. Endometrial cancer, addition of trastuzumab to chemotherapeutic agents like Carboplatin/Paclitaxel has shown higher progression free survival of 12.6 months. (Read more)
In the space of liquid tumors such as acute lymphoblastic leukemia (ALL), the FDA has expanded approval of Blinatumumab for treatment of MRD-positive ALL patients who are already in remission. The drug is able to enhance the immune cell attack on leukemia cells. Its side effects when used to treat MRD-positive B-cell precursor ALL have been found to be consistent with its use in other areas. (Read more)
